Evidence map›Paper›PMID 38691615›Full record

ArticleScience advances2024

D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease.

Ke Hou, Hope Pan, Hedieh Shahpasand-Kroner, Carolyn Hu, Romany Abskharon, Paul Seidler, Marisa Mekkittikul, Melinda Balbirnie, Carter Lantz, Michael R Sawaya and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Light-Triggered Disassembly of Peptide Nanostructures.Chembiochem : a European journal of chemical biology · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Ke HouDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-3869-2076
Hope PanDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0001-6509-6224
Hedieh Shahpasand-KronerDepartment of Neurology, UCLA, Los Angeles, CA, USA.ORCID 0009-0006-6724-3551
Carolyn HuDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0001-6218-4034
Romany AbskharonDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-1350-0189
Paul SeidlerDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0001-8530-7244
Marisa MekkittikulDepartment of Neurology, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-1739-9452
Melinda BalbirnieDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-3497-392X
Carter LantzDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.
Michael R SawayaDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-0874-9043
Joshua L DolinskyDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.
Mychica JonesDepartment of Neurology, UCLA, Los Angeles, CA, USA.ORCID 0009-0007-0697-3179
Xiaohong ZuoDepartment of Neurology, UCLA, Los Angeles, CA, USA.
Joseph A LooDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0001-9989-1437
Sally FrautschyDepartment of Neurology, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-0194-0363
Greg ColeDepartment of Neurology, UCLA, Los Angeles, CA, USA.ORCID 0000-0002-6848-7455
David S EisenbergDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, CA, USA.ORCID 0000-0003-2432-5419
Howard Hughes Medical Institute · USVA Greater Los Angeles Healthcare System · USUniversity of California, Los Angeles · USUniversity of Southern California · US

Funding

Towards Treatment of Alzheimer’s Disease by Targeting Pathogenic Tau and Beta-Amyloid StructuresR01AG070895 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVID EISENBERG · 2022 to 2026
$5.8M
Metabolic and Vascular Factors in tau pathogenesisR01AG066212 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FRAUTSCHY, SALLY ANN · 2020 to 2024
$3.4M
Seeds and Strains Derived from Tau Monomer - Perez Diversity SupplementRF1AG065407 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI DIAMOND, MARC I, JOACHIMIAK, LUKASZ A. · 2020 to 2021
$3.2M
Advancing Mass Spectrometry Analyses of Proteins, Assemblies, and ProteoformsR35GM145286 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A Loo · 2022 to 2026
$1.9M
Human tau neurodegeneration in Alzheimer'sR01AG021975 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FRAUTSCHY, SALLY ANN · 2004 to 2008
$1.2M
Modulation of tau pathogenesis by high dietary fat, gender and ApoE isoformR21AG050269 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FRAUTSCHY, SALLY ANN · 2016 to 2017
$347k
BLRD VA I01 BX004332BLRD VA I01 BX005919NIA NIH HHS R01 AG021975NIA NIH HHS R01 AG066212NIA NIH HHS R01 AG070895NIA NIH HHS R21 AG050269NIA NIH HHS RF1 AG065407NIGMS NIH HHS R35 GM145286
6 · The paper itself

Abstract

Amyloid fibrils of tau are increasingly accepted as a cause of neuronal death and brain atrophy in Alzheimer's disease (AD). Diminishing tau aggregation is a promising strategy in the search for efficacious AD therapeutics. Previously, our laboratory designed a six-residue, nonnatural amino acid inhibitor D-TLKIVW peptide (6-DP), which can prevent tau aggregation in vitro. However, it cannot block cell-to-cell transmission of tau aggregation. Here, we find D-TLKIVWC (7-DP), a d-cysteine extension of 6-DP, not only prevents tau aggregation but also fragments tau fibrils extracted from AD brains to neutralize their seeding ability and protect neuronal cells from tau-induced toxicity. To facilitate the transport of 7-DP across the blood-brain barrier, we conjugated it to magnetic nanoparticles (MNPs). The MNPs-DP complex retains the inhibition and fragmentation properties of 7-DP alone. Ten weeks of MNPs-DP treatment appear to reverse neurological deficits in the PS19 mouse model of AD. This work offers a direction for development of therapies to target tau fibrils.

Indexed as

Alzheimer DiseaseDisease Models, AnimalMagnetite Nanoparticlestau ProteinsAmyloidAnimalsBehavior, AnimalBrainHumansMiceMice, TransgenicPeptidesProtein Aggregation, PathologicalAmyloidMagnetite NanoparticlesPeptidestau Proteins

Identifiers

PMID38691615
PMCPMC11062580
OpenAlexW4396541709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.